Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE issues guidance on bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Published: 18 July 2013

The National Institute for Health and Care Excellence (NICE) has issued guidance to the health service on the use of bevacizumab for the treatment of advanced ovarian cancer, based on a report produced by SHTAC.

NICE has issued guidance to the health service in England and Wales that bevacizumab in combination with paclitaxel and carboplatin is not recommended for first-line treatment of advanced ovarian cancer.

NICE's guidance is based on an evidence review group report prepared by SHTAC, which critically appraised the drug manufacturer's submission to NICE's Single Technology Appraisal process.

The current standard management of advanced ovarian cancer in the NHS in England and Wales consists of chemotherapy with paclitaxel and carboplatin for first-line treatment after debulking surgery. Bevacizumab is a humanised monoclonal antibody that inhibits both vascular endothelial growth factor (VEGF)-induced signalling and VEGF-driven angiogenesis. This reduces vascularisation of tumours, thereby inhibiting tumour growth. Bevacizumab is administered by intravenous infusion.

For more information on SHTAC's research into cancer please visit our Research page.

Privacy Settings